Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations.
Abhishek Kumar VermaShea LoweryLi-Chin LinEazhisaivallabi DuraisamiJuan E Abrahante LlorénsQiang QiuMarco HeftiC Ron YuMark W AlbersStanley PerlmanPublished in: bioRxiv : the preprint server for biology (2024)
Post-Acute Sequelae of COVID-19 (PASC) encompasses persistent neurological symptoms, including olfactory and autonomic dysfunction. Here, we report chronic neurological dysfunction in mice infected with a virulent mouse-adapted SARS-CoV-2 that does not infect the brain. Long after recovery from nasal infection, we observed loss of tyrosine hydroxylase (TH) expression in olfactory bulb glomeruli and neurotransmitter levels in the substantia nigra (SN) persisted. Vulnerability of dopaminergic neurons in these brain areas was accompanied by increased levels of proinflammatory cytokines and neurobehavioral changes. RNAseq analysis unveiled persistent microglia activation, as found in human neurodegenerative diseases. Early treatment with antivirals (nirmatrelvir and molnupiravir) reduced virus titers and lung inflammation but failed to prevent neurological abnormalities, as observed in patients. Together these results show that chronic deficiencies in neuronal function in SARS-CoV-2-infected mice are not directly linked to ongoing olfactory epithelium dysfunction. Rather, they bear similarity with neurodegenerative disease, the vulnerability of which is exacerbated by chronic inflammation.
Keyphrases
- sars cov
- oxidative stress
- cerebral ischemia
- end stage renal disease
- respiratory syndrome coronavirus
- drug induced
- climate change
- endothelial cells
- coronavirus disease
- white matter
- high fat diet induced
- newly diagnosed
- resting state
- ejection fraction
- chronic kidney disease
- inflammatory response
- liver failure
- subarachnoid hemorrhage
- spinal cord
- prognostic factors
- peritoneal dialysis
- insulin resistance
- physical activity
- patient reported outcomes
- dna methylation
- spinal cord injury
- genome wide
- hepatitis b virus
- induced pluripotent stem cells
- acute respiratory distress syndrome
- adverse drug
- combination therapy